Of interest, a currently active phase II/III clinical trial is studying the clinical efficacy of NAM when prescribed synergistically with the EGFR (Epidermal growth factor receptor) inhibitors gefitinib or erlotinib in EGFR-mutated advanced NSCLC patients (NCT02416739). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.